HEM iSMART-D: Trametinib + Dexamethasone + Chemotherapy in Children With Relapsed or Refractory Hematological Malignancies

HEM-iSMART is a master protocol which investigates multiple investigational medicinal products in children, adolescents and young adults (AYA) with relapsed/refractory (R/R) ALL and LBL. Sub-protocol D is a phase I/II trial evaluating the safety and efficacy of trametinib in combination with dexamethasone, cyclophosphamide and cytarabine in children and AYA with R/R ped ALL/LBL whose tumor present with alterations in the RAS-RAF-MAPK pathway.

Trial Details

NCT ID
NCT05658640
Phase
PHASE1 / PHASE2
Sponsor
Princess Maxima Center for Pediatric Oncology
Status
RECRUITING
Cancer Type
T-Cell Lymphoma Lymphoma
Interventions
  • Trametinib
  • Dexamethasone
  • Cyclophosphamide
  • Cytarabine
  • Intrathecal chemotherapy
Locations (sample)
  • Vienna, Austria|48.20849,16.37208
  • Ghent, Belgium|51.05,3.71667
  • Copenhagen, Denmark|55.67594,12.56553
  • Helsinki, Finland|60.16952,24.93545
  • Bordeaux, France|44.84124,-0.58046

Key Eligibility Criteria

  • Children between 1 year (≥ 12 months) and 18 years of age at the time of first diagnosis and less than 21 years at the time of inclusion. Patients …
  • Performance status: Karnofsky performance status (for patients \>12 years of age) or Lansky Play score (for patients
  • 12 years of age) ≥ 50% (Appendix I).
  • Written informed consent from parents/legal representative, patient, and age-appropriate assent before any study specific screening procedures are …

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find T-Cell Lymphoma Lymphoma Trials on Trialify →